Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.
Jacobus
N V
NV
Medical Research Division, American Cyanamid Company, Lederle Laboratories, Pearl River, New York 10965.
Immermann
F W
FW
Gupte
J M
JM
Testa
R T
RT
D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000008:administration & dosage; D010878:Piperacillin / Q000008:administration & dosage; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin